Let's continue to see the hot AI money rotate into $HIMS. Reaccelerating growth story and global reach has been largely ignored. With $HIMS you get healthcare (defensive), growth and AI. Hard to find companies with all 3 aspects.
AI compute may be scarce, but it won't be forever. Health, longevity and time is always scarce. $HIMS can extend the most valuable resource--time. Not just any time, but a longer life of health where you feel great & can still experience life. You're going to be able to buy it.
$DOCN is in the process of being re-rated. Not yet to the extent of memory & chip stocks. It is the cost-effective AI agentic play. Businesses need affordable solutions, not frontier AI, otherwise, it's too expensive to use and margins get crushed. $DOCN is still undervalued IMO.
The $HIMS flywheel is exploding. Customer base is growing. Cross-sell opportunities are being magnified. $HIMS owns the customer relationships, not the drug companies. Health and longevity is buying time, which is the most valuable asset. We are still very early. Don't miss it.
@himshouse $BZRD BPI Labs future reverse merger possibility. Largest compounding pharmacy in Florida. Gotta believe they would be part of the peptide explosion.